Antech Launches trūRapid™ FOUR: Simplifying Canine Vector-Borne Disease Screening for Veterinarians
Antech, a global veterinary diagnostics, technology and imaging company, today announced the launch of trūRapid™ FOUR, a comprehensive in-house canine vector-borne disease (CVBD) screening test.
trūRapid™ FOUR is a lateral flow test used to detect canine antibodies to Anaplasma spp., Ehrlichia spp., and Lyme C6 ( Borrelia burgdorferi), as well as heartworm ( Dirofilaria immitis) antigen, using whole blood, serum, or plasma.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare's Science & Diagnostics division and Antech, said: 'With its speed, proven reliability, and streamlined workflow, trūRapid™ FOUR offers busy veterinary professionals a simple alternative to current testing protocols and, importantly, provides an affordable choice without compromising quality.'
Key Features of trūRapid™ FOUR include:
Streamlined Workflow: Requires just a few drops of sample, minimizing the need for additional blood draws or sample centrifugation. Eliminates manual snapping; the test reaction begins automatically when the sample and buffer is directly added.
Proven Reliability: Excellent sensitivity and specificity when compared to reference laboratory testing. For Lyme, C6 ensures high specificity, preventing false positives caused by vaccination.
Broad reactivity: E. canis, E. chaffeensis, and E. ewingii; A. phagocytophilum and A. platys.
No refrigeration: Tests can be stored at room temperature for their entire shelf life, saving refrigerator space, simplifying inventory management, and eliminating the need to warm up the test before use.
Eco-Friendly Design: Generates less plastic waste with no need for additional sample handling tubes — just the cartridge and a plastic pipette.
About Antech
Antech is a global veterinary diagnostics company, driven by our passion for innovation that helps veterinarians deliver better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services.
SOURCE: Antech
Copyright Business Wire 2025.
PUB: 03/10/2025 08:46 AM/DISC: 03/10/2025 08:47 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
DA Davidson Keeps Buy Rating on Shift4 Payments (FOUR)
On June 5, DA Davidson analysts maintained a Buy recommendation on Shift4 Payments, Inc. (NYSE:FOUR) with a $124 price target. The company has shown solid momentum, and the analysts' decision comes in light of Global Blue's financial results for the fourth fiscal quarter and full-year 2025. Shift4 announced the acquisition of Global Blue for $7.50 per common share in cash back in February 2025. A business person using a mobile point of sale device outside of a retail store. Global Blue disclosed a 20% year-over-year boost in total revenue, coming in at €508 million. The company's adjusted EBITDA grew 36% year-over-year and reached €202 million. However, even with these encouraging financials, DA Davidson analysts mentioned that they do not foresee notable changes to their initial forecasts of Shift4 numbers. Meanwhile, the Buy rating reflects steady confidence by analysts in the company. Shift4 Payments, Inc. (NYSE:FOUR) delivers end-to-end commerce solutions, combining modern POS systems with omnichannel payment processing across industries. With a growing footprint in hospitality, retail, and e-commerce, Shift4 is scaling through tech-forward solutions like SkyTab and Shift4Shop. The company was established in 1999 and is headquartered in Pennsylvania. While we acknowledge the potential of FOUR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure: None.
Yahoo
a day ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
